Welcome to our dedicated page for Sanofi FR SEC filings (Ticker: SNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a pharmaceutical filing can feel like deciphering a clinical trial protocol—especially when Sanofi’s pipeline updates, patent schedules, and vaccine safety tables sprawl across hundreds of pages. If you have ever searched for “Sanofi insider trading Form 4 transactions” or wondered where the next vaccine milestone is buried, you are not alone.
Stock Titan solves that problem. Our platform streams every document straight from EDGAR and delivers AI-powered summaries that highlight R&D spend, patent expirations, and litigation disclosures in seconds. Whether you need the latest Sanofi quarterly earnings report 10-Q filing, a Sanofi annual report 10-K simplified, or alerts on Sanofi Form 4 insider transactions real-time, each form lands here the moment it’s filed—already distilled into plain language.
Use our tools to:
- Track pipeline progress and revenue drivers with a single click through Sanofi earnings report filing analysis
- Follow executive moves via Sanofi executive stock transactions Form 4
- Receive instant context on Sanofi 8-K material events explained—from trial results to licensing deals
- Dive into Sanofi proxy statement executive compensation details without paging through appendices
Analysts, portfolio managers, and healthcare specialists rely on Stock Titan’s real-time updates, comprehensive coverage of ALL filing types, and expert commentary to turn dense disclosures into actionable insight. If understanding Sanofi SEC documents with AI is your goal, you are in the right place—complex science, clear filings.
Sanofi furnished a Form 6-K announcing a press release dated October 8, 2025. The release states that AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in a phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This update highlights mid-stage clinical results disclosed via an attached exhibit.
Sanofi reported two corporate developments in an exhibit list attached to its Form 6-K. A press release dated September 23, 2025, states that Sanofi's investigational medicine SAR446268 received U.S. Fast Track designation for the treatment of non-congenital myotonic dystrophy type 1, signaling accelerated regulatory review for that indication. A separate press release dated September 24, 2025, states Sanofi is committing an additional $625 million to Sanofi Ventures to boost investments in biotech and digital health innovation.
Both items are presented as exhibits to the current report and indicate near-term regulatory and strategic investment activity explicitly disclosed by the company.
Sanofi (SNY) filed a Form 6-K that includes an exhibit: a press release dated
The disclosure is concise: it notifies investors that a regulatory approval milestone was achieved for a new therapeutic option in immune thrombocytopenia and that the company has publicly released that information via a press release attached as Exhibit 99.1.
Sanofi filed a Form 6-K reporting an attached press release dated August 14, 2025, announcing that its investigational drug rilzabrutinib received orphan designation in the European Union for the treatment of IgG4-related disease. The filing includes the company signature block signed by Alexandra Roger, Head of Legal Corporate & Finance, dated August 29, 2025. The document is a brief disclosure of the press release and does not contain financial results, transaction details, or additional corporate commentary.
Amundi and Amundi Asset Management report beneficial ownership of 61,769,803 shares of Sanofi (common stock and ADRs), representing 5.03% of the class. The filing shows no sole voting or dispositive power and records shared voting power of 29,534,426 shares and shared dispositive power of 61,769,803 shares.
The filing discloses that 26,790,332 shares are held through an employee FCPE on which Amundi does not exercise voting rights; those voting rights are exercised by the FCPE supervisory board where employee representatives hold the majority. The reporting persons are organized in France and filed this Schedule 13G/A under the Securities Exchange Act.
FAQ
What is the current stock price of Sanofi FR (SNY)?
What is the market cap of Sanofi FR (SNY)?
